Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

For patients with cT1-T3 cN0 cM0 mid/low rectal cancer seeking organ preservation, what treatment approach do you recommend?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Medical College of Wisconsin

This is an important question; however, the answer is unknown. The key outcome that should be the focal point for the best treatment option, is which treatment strategy results in the most optimal patient reported quality of life and bowel function. Currently, this remains void of prospective, rando...

Should hippocampal-avoidance WBRT be the default option for WBRT?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of New Mexico School of Medicine

I think this is a difficult question to answer as a lot depends on the particulars. Here's a list of some of those issues: Radiosurgery is very easily administered & frequently free of toxicity. Systemic agents are showing improved efficacy in the brain. Surveillance MR imaging = lower incidence of ...

How long after achieving a CR would you consider stopping pembrolizumab in metastatic melanoma?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Institut Gustave Roussy

Based on Keynote 001 and more recently on Keynote 006, where we observed sustained remission in more than 90% of the patients who had stopped pembrolizumab for complete response, we usually consider stopping pembrolizumab in patients who have a confirmed complete response (this means that we have tw...

Do you use either memantine or hippocampal sparing technique to preserve cognitive function when giving whole brain radiotherapy?

4
7 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mayo Clinic

Dr. @Dr. First Last and I put together the response below:We use memantine and hippocampal sparing technique for all brain metastasis patients who are planning to receive WBRT. This is based off the recently published phase III trial NRG CC001 that found hippocampal avoidance WBRT plus memantine res...

What factors do you consider when selecting dose/fractionation for whole brain radiotherapy?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Columbia University Irving Medical Center

I assume this question is for brain metastases patients who are not eligible for hippocampal avoidance WBRT (ineligible criteria including but not limited to - mets 5 mm within either hippocampus, germ cell/small cell/lymphoma, leptomeningeal disease, etc.) - my default WBRT dose fractionation is 30...

What is the optimal duration of ADT in high-risk prostate cancer treated with RT+ADT?

18
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · Cedars-Sinai Medical Center

Nabib et al. presented "Final Results" of the 18 vs. 36 month ADT trial for high-risk M0 prostate cancer in Chicago during ASCO 2017. This trial has the potential to be practice changing, since most men receive 2+ years of ADT during RT-ADT for high-risk disease. 630 patients were randomized and OS ...

How should radiation oncology departments prepare for significant resource depletion and/or staff shortages with the COVID-19 outbreak?

6
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · Washington University School of Medicine

Resource depletion to the extreme would be analogous to having a non-operational clinic as some experienced during the Hurricane María disaster. I would suggest reading the paper:Lessons Learned From Hurricane Maria in Puerto Rico: Practical Measures to Mitigate the Impact of a Catastrophic Natural ...

What resection margins are required for DCIS with a component of invasive disease?

3
5 Answers

Mednet Member
Mednet Member
Radiation Oncology · Beth Israel Deaconess Medical Center

The SSO-ASTRO-ASCO guidelines of 2016 on margin status for patients with tumors that are pure DCIS or predominantly DCIS requiring a minimum of 2 mm for those receiving RT were based on a meta-analysis of (mostly older) published studies, not individual patient data. Three much more recent studies f...

How do you sequence radiation and capecitabine in breast cancer patients receiving adjuvant capecitabine for residual disease after neoadjuvant chemotherapy?

21
6 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mayo Clinic, Rochester, MN

According to personal communication with Dr. Masakazu Toi (June 13, 2017), the corresponding author of the CREATE-X NEJM publication, radiotherapy was administered prior to capecitabine in the majority of cases on this study. It is worth noting that in CALGB 49907, a randomized trial comparing capec...

How are you using predictive tests such as DCISionRT (PreludeDx) or OncotypeDX DCIS in the management of DCIS?

14
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · USC Keck School of Medicine

Advantages: It's a relatively cheap, simple assay to better individualize risk of DCIS. Not only prognostic like Oncotype DCIS but also predictive of the absolute benefit of radiation. Supposed to be a better risk assessment tool than traditional clinical pathologic factors. Can identify those who ...